Compare GSK Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA STRIDES PHARMA SCIENCE GSK PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 52.1 14.8 352.1% View Chart
P/BV x 11.0 0.9 1,253.5% View Chart
Dividend Yield % 1.4 0.6 259.9%  

Financials

 GSK PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
GSK PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3,5951,147 313.4%   
Low Rs1,253642 195.2%   
Sales per share (Unadj.) Rs184.7317.2 58.2%  
Earnings per share (Unadj.) Rs26.37.8 335.2%  
Cash flow per share (Unadj.) Rs29.225.1 116.4%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.80.2 369.0%  
Book value per share (Unadj.) Rs126.3274.3 46.1%  
Shares outstanding (eoy) m169.4089.50 189.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x13.12.8 465.6%   
Avg P/E ratio x92.2114.0 80.9%  
P/CF ratio (eoy) x83.135.7 232.8%  
Price / Book Value ratio x19.23.3 588.4%  
Dividend payout %76.125.5 298.4%   
Avg Mkt Cap Rs m410,62680,058 512.9%   
No. of employees `0005.02.5 197.8%   
Total wages/salary Rs m5,3724,341 123.8%   
Avg. sales/employee Rs Th6,306.711,325.8 55.7%   
Avg. wages/employee Rs Th1,083.11,731.4 62.6%   
Avg. net profit/employee Rs Th898.0280.1 320.6%   
INCOME DATA
Net Sales Rs m31,28128,394 110.2%  
Other income Rs m1,023941 108.8%   
Total revenues Rs m32,30429,334 110.1%   
Gross profit Rs m6,0093,965 151.5%  
Depreciation Rs m4861,540 31.6%   
Interest Rs m61,962 0.3%   
Profit before tax Rs m6,5401,403 466.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m287-436 -65.9%   
Tax Rs m2,37397 2,438.8%   
Profit after tax Rs m4,454702 634.4%  
Gross profit margin %19.214.0 137.5%  
Effective tax rate %36.36.9 523.3%   
Net profit margin %14.22.5 575.8%  
BALANCE SHEET DATA
Current assets Rs m20,06124,836 80.8%   
Current liabilities Rs m14,54318,993 76.6%   
Net working cap to sales %17.620.6 85.7%  
Current ratio x1.41.3 105.5%  
Inventory Days Days5771 80.0%  
Debtors Days Days14113 12.4%  
Net fixed assets Rs m14,34334,289 41.8%   
Share capital Rs m1,694895 189.3%   
"Free" reserves Rs m19,70423,651 83.3%   
Net worth Rs m21,39824,546 87.2%   
Long term debt Rs m215,513 0.0%   
Total assets Rs m39,11365,437 59.8%  
Interest coverage x1,091.01.7 63,613.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.4 184.3%   
Return on assets %11.44.1 280.0%  
Return on equity %20.82.9 727.7%  
Return on capital %31.96.9 463.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53415,697 3.4%   
Fx outflow Rs m7,091735 964.2%   
Net fx Rs m-6,55714,962 -43.8%   
CASH FLOW
From Operations Rs m3,9941,871 213.5%  
From Investments Rs m-1,4335,826 -24.6%  
From Financial Activity Rs m-3,584-10,157 35.3%  
Net Cashflow Rs m-1,023-2,615 39.1%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 37.8 27.0%  
FIIs % 23.8 8.6 276.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 25.9 59.5%  
Shareholders   102,036 56,241 181.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS